Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Giacomelli

Showing results (71-80 of 80) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 80 results.
Annals of the Rheumatic Diseases|July 26, 2008
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsJ H W Distler, Y Allanore, J Avouac, et al.
Brain, Behavior, and Immunity|July 13, 2025
Upadacitinib regulates pain-related pathways and BDNF expression in human monocyte-derived microglial-like cellsM Vomero, E Corberi, O Berardicurti, et al.
Clinical and Experimental Medicine|November 4, 2019
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control studyM Prete, E Favoino, R Giacomelli, et al.
Scandinavian Journal of Rheumatology|October 1, 2014
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre studyL Quartuccio, M Isola, C Baldini, et al.
Clinical and Experimental Rheumatology|September 22, 2005
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn)F Bandinelli, F Bartoli, E Perfetto, et al.
Annals of the Rheumatic Diseases|April 17, 2001
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)M Matucci-Cerinic, R Giacomelli, A Pignone, et al.
Annals of the Rheumatic Diseases|May 1, 2008
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosisV Liakouli, M Manetti, A Pacini, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centresJ Fransen, D Popa-Diaconu, R Hesselstrand, et al.
Annals of the Rheumatic Diseases|May 15, 2001
European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centresA Della Rossa, G Valentini, S Bombardieri, et al.
Annals of the Rheumatic Diseases|May 15, 2001
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexesG Valentini, A Della Rossa, S Bombardieri, et al.
Pageof 8

Showing results (71-80 of 80) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 80 results.
Annals of the Rheumatic Diseases|July 26, 2008
EULAR Scleroderma Trials and Research group statement and recommendations on endothelial precursor cellsJ H W Distler, Y Allanore, J Avouac, et al.
Brain, Behavior, and Immunity|July 13, 2025
Upadacitinib regulates pain-related pathways and BDNF expression in human monocyte-derived microglial-like cellsM Vomero, E Corberi, O Berardicurti, et al.
Clinical and Experimental Medicine|November 4, 2019
Evaluation of the influence of social, demographic, environmental, work-related factors and/or lifestyle habits on Raynaud's phenomenon: a case-control studyM Prete, E Favoino, R Giacomelli, et al.
Scandinavian Journal of Rheumatology|October 1, 2014
Clinical and biological differences between cryoglobulinaemic and hypergammaglobulinaemic purpura in primary Sjögren's syndrome: results of a large multicentre studyL Quartuccio, M Isola, C Baldini, et al.
Clinical and Experimental Rheumatology|September 22, 2005
The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn)F Bandinelli, F Bartoli, E Perfetto, et al.
Annals of the Rheumatic Diseases|April 17, 2001
Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)M Matucci-Cerinic, R Giacomelli, A Pignone, et al.
Annals of the Rheumatic Diseases|May 1, 2008
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosisV Liakouli, M Manetti, A Pacini, et al.
Annals of the Rheumatic Diseases|July 26, 2011
Clinical prediction of 5-year survival in systemic sclerosis: validation of a simple prognostic model in EUSTAR centresJ Fransen, D Popa-Diaconu, R Hesselstrand, et al.
Annals of the Rheumatic Diseases|May 15, 2001
European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centresA Della Rossa, G Valentini, S Bombardieri, et al.
Annals of the Rheumatic Diseases|May 15, 2001
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexesG Valentini, A Della Rossa, S Bombardieri, et al.
Pageof 8